Gewinn- und Verlust:

LEAWOOD, Kan., April 22, 2025 (GLOBE NEWSWIRE) -- First Busey Corporation (Nasdaq: BUSE) reports first quarter results.

CHAMPAIGN, Il. and LEAWOOD, Kan.

Although the revenue and EPS for CrossFirst (CFB) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CrossFirst Bankshares (CFB) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.39 per share a year ago.

LEAWOOD, Kan., Jan. 28, 2025 (GLOBE NEWSWIRE) -- CrossFirst Bankshares, Inc. (Nasdaq: CFB), the bank holding company for CrossFirst Bank, today reported operating results for the fourth quarter and full-year ended December 31, 2024.

CHAMPAIGN, Ill. and LEAWOOD, Kan.

CHAMPAIGN, Ill. and LEAWOOD, Kan.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. “Dysregulated activation of the complement sy.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CrossFirst Bankshares, Inc. (NasdaqGS: CFB) to First Busey Corporation (NasdaqGS: BUSE). Under the terms of the proposed transaction, shareholders of CrossFirst will receive 0.6675 shares of First Busey common stock for each share of CrossFirst that they own. KSF is seeking to determine whether this considerat.

CrossFirst (CFB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).